Bookmark and Share

Wilbur H. Chen

Wilbur H. Chen M.D., M.S.

Academic Title: Associate Professor
Primary Appointment: Medicine
Location: HSF1, 480
Phone: (410) 706-5328
Fax: (410) 706-6205

Research Interests:

Dr. Chen is an adult infectious disease physician-scientist with a specific interest in clinical vaccinology. He is Chief of the Adult Clinical Studies section within the Center for Vaccine Development and Director of the UMB Travelers' Health Clinic. His research is concentrated on two areas of global health importance . First, he is devoted to developing vaccines for enteric pathogens, infectious diseases chiefly of resource poor and economically disadvantaged countries. Second, he is interested in developing improved vaccines for the elderly, a rapidly growing segment of the global population which is susceptible to many infections and a special population that generally responds poorly to vaccination. 

Dr. Chen is active investigator within the NIAID-supported Vaccine and Treatment Evaluation Unit (VTEU), composed of 9 academic centers throughout the U.S., and was the principal investigator of the NIAID-supported Food and Waterborne Diseases Integrated Research Network Clinical Research Unit (FWD IRN CRU). He has been a PI on vaccine trials for: influenza viruses (Seasonal, Pandemic 2009 H1N1, Avian H5N1, and Avian H7N9 influenza), agents of bioterror (Tularemia and Staphylococcal enterotoxin B), and enteric pathogens (typhoid, cholera and enterotoxigenic E. coli)-including human experimental challenge studies with wild-type V. cholerae and enterotoxigenic E. coli (ETEC).

In collaboration with PATH (an international nonprofit organization, Program for Appropriate Technology in Health), Dr. Chen has imminent research projects evaluating Shigella vaccines and developing a human challenge model with heat-stable enterotoxin (ST)-only expressing ETEC. With funding from the Bill & Melinda Gates Foundation, Dr. Chen is also developing a human challenge model with Cryptosporidium hominis.

Lastly, Dr. Chen has a translational laboratory research program that uses murine models of infection-primarily focused on models of pneumonia which are used to study the innate immune response and evaluate candidate therapeutics.


Last three years

  1. Ajao AO, Harris AD, Johnson JK, Roghmann M, Perencevich EN, Schweizer ML, Zhan M, Chen WH, Furuno JP. Association between Methicillin-resistant Staphylococcus aureus Colonization and Infection May not Differ by Age Group. Infect Control Hosp Epidemiol 2013; 34:93-5.
  2. Shirey KA, Lai W, Scott A, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini JL, Weiss J, Chen WH, Ernst R, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN. The TLR4 Antagonist, Eritoran, Protects Mice from Lethal Influenza Infection.  Nature 2013; 497:498-502.
  3. El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, and Chen WH. Safety and Immunogenicity of a Single Oral Dose of Recombinant Double-Mutant Heat-Labile Toxin (dmLT) Derived from Enterotoxigenic Escherichia coli (ETEC). Clin Vac Immunol 2013; 20:1764-70.
  4. Chen WH, Greenberg RN, Pasetti MF, Livio S, Lock M, Gurwith M, and Levine MM. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR prepared from new master and working cell banks. Clin Vac Immunol 2014; 21:66-73.
  5. Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With or Without AS03 Adjuvant. Open Forum Infect Dis 2014; 1(3):ofu091.
  6. Stamatos NM, Zhang L, Jokilammi A, Finne J, Chen WH, El-Maarouf A, Cross A, and Hankey KG. Changes in Polysialic Acid Expression on Myeloid Cells during Differentiation and Recruitment to Sites of Inflammation: Role in Phagocytosis. Glycobiology 2014; 24:864-79.
  7. Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Jiang X, Vinje J, Gregoricus N, Chen WH, Frenck RW, Moe C, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 2015; 211:870-8.
  8. Callahan ST, Wolff M, Hill HR, and Edwards KM. Acknowledged as member of NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group. Impact of Body Mass Index on Immunogenicity of Pandemic H1N1 Vaccine in Children and Adults. J Infect Dis 2014; 210: 1270-74.
  9. Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR. Immunogenicity of avian influenza A/Anhui/01/2005 (H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1420-28.
  10. Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, Goodwin R, Borkowski A, Clemens R, Mendelman PM. A Novel Intramuscular Bivalent Norovirus VLP Vaccine Candidate – Reactogenicity, Safety and Immunogenicity in a phase I trial in healthy adults. J Infect Dis 2014; 210:1763-71.
  11. Chen WH, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein DA, Hall R, Cohen MB. The safety and immunogenicity of escalating dosages of a single oral administration of Peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli (ETEC) and Vibrio cholerae. Clin Vac Immunol 2015; 22: 129-35.
  12. Sundararajan A, Sangster MY, Frey S, Atmar R, Chen WH, Ferreira J, Bargatze R, Mendelman PM, Treanor JJ, Topham DJ. Robust Mucosal-homing Antibody-secreting B cell Responses Induced by Intramuscular Administration of Adjuvanted Bivalent Human Norovirus-like Particle Vaccine. Vaccine 2015; 33:568-76.
  13. Nita-Lazar M, Banerjee A, Feng C, Amin MN, Frieman MB, Chen WH, Cross AS, Wang L-X, Vasta GR. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. Molec Immunol 2015; 65:1-16.
  14. Winokur P, Patel S, Brady R, Chen WH, Edwards K, Creech CB, Frey S, Belshe R, Walter E, Bellamy A, Hill H. Safety and Immunogenicity of a Single Low or High Dose of Clade 2 H5N1 Inactivated Influenza Vaccine in Adults Previously Primed with Clade 1 H5N1 Vaccine. J Infect Dis 2015; 212: 525-30.
  15. Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinje J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowshi A, Baehner F, Goodwin R, Edmonds A, Mendelman PM. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vacc Immunol 2015; 22: 923-9.
  16. Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton J, El Sahly H, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Chaplin P, Belshe RB, the DMID 09-0002 MVA Study Group, Anderson EL, Graham IL, Johnston C, Mulligan M, Rouphael N, Atmar R, Patel S, Chen W, Kotloff K, Creech CB. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine 2015; 33: 5225-34.
  17. Jackson SS and Chen WH. The evidence for CVD 103-HgR as an effective single dose oral cholera vaccine. Future Microbiology 2015; 10: 1271-81.
  18. Omer SB, Richards JL, Madhi SA, Tapia MD, Steinhoff MC, Aqil AR, Wairagkar N; acknowledged as member of the BMGF Supported Maternal Influenza Immunization Trials Investigators Group. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: Methods and expectations. Vaccine 2015: 33:3801-12.
  19. Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vacc Immunol (in press).
  20. Mbawuike I, Atmar RL, Patel SM, Corry D, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA. Cell Mediated Immune Responses Following Revaccination with an Influenza A/H5N1 Vaccine. Vaccine (in press).